Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures (2018 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Gains from Sales and Divestitures readings, the most recent being $21474.0 for Q1 2026.

  • On a quarterly basis, Gains from Sales and Divestitures fell 60.49% to $21474.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $21474.0, a 60.49% decrease, with the full-year FY2025 number at $771693.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures hit $21474.0 in Q1 2026 for Kiniksa Pharmaceuticals International, down from $771693.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $771693.0 in Q4 2025 to a low of $21474.0 in Q1 2026.
  • Median Gains from Sales and Divestitures over the past 5 years was $250805.0 (2022), compared with a mean of $300577.7.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 103.31% in 2023 and later plummeted 60.49% in 2026.
  • Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures stood at $250805.0 in 2022, then soared by 85.76% to $465891.0 in 2023, then grew by 29.59% to $603762.0 in 2024, then increased by 27.81% to $771693.0 in 2025, then plummeted by 97.22% to $21474.0 in 2026.
  • The last three reported values for Gains from Sales and Divestitures were $21474.0 (Q1 2026), $771693.0 (Q4 2025), and $698136.0 (Q3 2025) per Business Quant data.